ArriVent BioPharma (AVBP) Free Cash Flow (2023 - 2026)

ArriVent BioPharma has disclosed Free Cash Flow across 4 years of filings, most recently posting -$41.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$41.9 million, up 38.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$134.5 million (down 12.44% YoY), and the FY2025 annual result was -$160.6 million, down 128.72% from the prior year.
• Free Cash Flow came in at -$41.9 million for Q1 2026 at ArriVent BioPharma, down from -$30.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$8.6 million in Q2 2023 to a low of -$68.0 million in Q1 2025.
• The 4-year median for Free Cash Flow is -$18.6 million (2024), against an average of -$25.3 million.
• Across the five-year window, Free Cash Flow tumbled 265.08% in 2025 and soared 38.4% in 2026, its largest moves.
• ArriVent BioPharma's Free Cash Flow stood at -$14.9 million in 2023, then dropped by 8.31% to -$16.2 million in 2024, then sank by 89.81% to -$30.7 million in 2025, then tumbled by 36.64% to -$41.9 million in 2026.
• The last three Free Cash Flow figures came in at -$41.9 million (Q1 2026), -$30.7 million (Q4 2025), and -$35.8 million (Q3 2025), per Business Quant data.